1.11597
Parteck® SI 400 LEX (Sorbitol)
EMPROVE® EXPERT, Ph. Eur., BP, NF, JP
Pharma Manufacturing
Synonym(s):
Parteck® Sorbitol, D-Glucitol
About This Item
Recommended Products
Agency
BP
JP
NF
Ph. Eur.
Quality Level
product line
EMPROVE® EXPERT
form
solid
autoignition temp.
420 °C
pH
6-7 (20 °C, 100 g/L in H2O)
mp
94-96 °C
transition temp
flash point >100 °C
solubility
2350 g/L
density
1.49 g/cm3 at 20 °C
application(s)
liquid formulation
ophthalmics
parenterals
pharmaceutical
storage temp.
2-25°C
SMILES string
OC(C(O)C(O)CO)C(O)CO
InChI
1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2
InChI key
FBPFZTCFMRRESA-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
As part of our Emprove® Program, our raw materials are offered with extensive documentation facilitating compliance of your pharma and biopharma product, full supply chain transparency and risk mitigation. Our SAFC® portfolio of high-quality products for biopharmaceutical and pharmaceutical formulation and production withstands strict quality control procedures and is produced according to applicable cGMP guidelines.
Application
Legal Information
Application
also commonly purchased with this product
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
What is the Emprove® Program?
The Emprove® Program is a system providing comprehensive and thorough documentation of our filters and single-use components, pharma raw materials, and starting materials. Four document types are included with an Emprove® Program subscription:
Free of charge - Sign in to download
Free of charge - Sign in to download
Free of charge - Sign in to download
Available by subscription or for a fee
Available by subscription or for a fee
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
This overview describes the challenges when developing parenteral formulations and strategies to overcome them and reduce the risk of production.
This overview describes the challenges when developing parenteral formulations and strategies to overcome them and reduce the risk of production.
This overview describes the challenges when developing parenteral formulations and strategies to overcome them and reduce the risk of production.
This overview describes the challenges when developing parenteral formulations and strategies to overcome them and reduce the risk of production.
Related Content
Learn more on mAb subcutaneous or intravenous formulation, and the relevant associated products, including excipients.
Learn more on mAb subcutaneous or intravenous formulation, and the relevant associated products, including excipients.
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service